Why Johnson & Johnson’s CEO Welcomes Scrutiny
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Is Johnson & Johnson Stock a Buy?
The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...
Johnson & Johnson price target raised to $166 from $162 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...
Barchart on MSN1d
Johnson & Johnson Stock Outlook: Is Wall Street Bullish or Bearish?
New Brunswick, New Jersey-based Johnson & Johnson (JNJ) researches, develops, manufactures, and sells various products in the ...
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Nets Rumors: Cam Johnson Asking Price Standing in Way of Trade at 2025 NBA Deadline
Brooklyn Nets wing Cam Johnson is available for a deal, but it's possible he'll stay in town after Thursday's trade deadline.
Super Bowl 2025: Eagles' Lane Johnson reveals how long he'll continue playing, has timetable for NFL exit
Lane Johnson assured he was coming back for the 2025 season, which would be his 13th in the NFL. Johnson is still an All-Pro ...
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...